Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies

Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies

PURCHASE, N.Y., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates...

Cognition and FDA align on Phase 3 study of zervimesine in DLB - BioTuesdays

Cognition Therapeutics (NASDAQ: CGTX) has announced alignment with the FDA on key elements of a Phase 3 study of either 100 mg of oral zervimesine or placebo for nine months in mild-to-moderate dementia with Lewy bodies (DLB) including patient selection, dose, duration, and endpoints. According to Cognition, the study will use a neuropsychiatric inventory that […]

Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies - PressReach

PURCHASE, N.Y., Oct. 22, 2026 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, has aligned with the U.S. Food and Drug Administration (FDA) on key elements of a Phase 3 study in dementia with Lewy bodies (DLB) including patient selection, dose, … Continue reading "Cognition Therapeutics Announces Alignment wit…